On day 3 of the AACR 2018 Annual Meeting in Chicago, IsoPlexis scientific advisory board member Antoni Ribas, director of the tumor immunology program at UCLA's Jonsson Comprehensive Cancer Center, presented "Enhanced expansion and tumor targeting of adoptively transferred T cells with NKTR-214". He highlighted findings from a study looking at the effectiveness of ACT in combination with the cytokine agonist NKTR-214, produced by San Francisco-based biopharma company Nektar Therapeutics, which also participated in the study. The study found that the ACT-NKTR-214 combination improved the induction of cytotoxic T cells and increased their polyfunctionality, indicating that addition of NKTR-214 could boost the performance of ACT.